Sentynl Therapeutics

Sentynl Therapeutics is a private, commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company has achieved a significant milestone with the FDA approval of ZYCUBO® (copper histidinate), indicating a transition from development to commercialization. Led by a seasoned executive team with extensive experience in specialty pharma startups and product launches, Sentynl operates on guiding principles of impact, innovation, and integrity to address unmet medical needs in niche patient populations.

Specialty pharma model focused on identifying, developing, and commercializing therapies for rare diseases; not a proprietary technological platform.

Competition exists from other specialty pharma and biotech companies focused on rare diseases, as well as larger pharmaceutical firms with orphan drug divisions. Success depends on effective commercialization in niche markets, differentiated patient support services, and the ability to secure and maintain favorable reimbursement.